Galena Biopharma, Inc. (GALE) To Deliver Presentation At The 2014 Leerink Global Healthcare Conference

Feb. 06, 2014 2:45 PM ETSLS
MissionIR profile picture
MissionIR's Blog
133 Followers
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Small cap

Contributor Since 2010

We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to building shareholder value. View our website at www.MissionIR.com MissionIR provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.missionir.com.

Today before the opening bell, Galena Biopharma announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer, will be presenting a corporate update at the 2014 Leerink Global Healthcare Conference. The presentation will take place on Wednesday, February 12, 2014 at 3:55 p.m. ET at the Waldorf Astoria Hotel in New York, New York.

The presentation will be webcast and available on the investors section of the company's website at galenabiopharma.com.

Galena Biopharma is focused on developing and commercializing targeted oncology treatments to address major unmet medical needs and advance cancer care. The company's peptide vaccine immunotherapies harness the patient's own immune system to identify and destroy cancer cells. Utilizing peptide immunogens has many clinical advantages, including an excellent safety profile and long-lasting protection through immune system activation and convenient delivery.

MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.